CLINICAL_TRIALS
trial_result
· 2012-05-31
Clinical Trial Update: Bilastine Updosing - Characterization of Underlying Mechanisms [Phase 2, Phase 3]
Summary
An update on a completed Phase 2/3 trial of bilastine dosing to characterize the underlying mechanisms in cold contact urticaria.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Charite University, Berlin, Germany | Conditions: Cold Contact Urticaria | Phase 2, Phase 3 | Status: COMPLETED